Novo Nordisk A/S President and CEO Lars Jorgensen mostly parried challenges to the company’s US pricing for its mega-blockbusters Ozempic and Wegovy at a Senate Health, Education, Labor and Pensions Committee hearing, using traditional counter arguments.
Key Takeaways
-
Senate HELP Committee Chair Bernie Sanders wants Novo Nordisk to commit to reduced list prices for Ozempic and Wegovy in return for assurances from the major PBMs to provide preferential access to the drugs.
-
Novo CEO Lars Jorgensen was skeptical of the commitments, saying the company’s recent experience with lowering list prices for insulin suggests access may not be assured
He argued during the 24 September hearing that rebates already reduce the net price of the drugs significantly and was skeptical that pharmacy benefit managers would maintain
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?